Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Public ClinicalTrials.gov record NCT02503423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.
Study identification
- NCT ID
- NCT02503423
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 253 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 14, 2015 (Actual)
- Primary completion
- Oct 2022 (Actual)
- Completion
- Dec 2027 (Estimated)
- Last update posted
- Mar 20, 2026
2015 – 2027
United States locations
- U.S. sites
- 31
- U.S. states
- 22
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| HonorHealth Research Institute | Scottsdale | Arizona | 852558 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| UC Davis Medical Center | Sacramento | California | 95817 | — |
| Simlow Cancer Hospital at Yale | New Haven | Connecticut | 06510 | — |
| Emory University winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Chicago | Illinois | 60611 | — |
| The Sidney Kimmel Comprehensive Cancer Center at John Hopkins | Baltimore | Maryland | 21287 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Dartmouth-Hitchcock Medical Center (DHMC) | Lebanon | New Hampshire | 03766 | — |
| Summit Medical Group - Florham Park Campus/Atlantic Health | Florham Park | New Jersey | 07932 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| New York Presbyterian Hospital Columbia University Medical Center | New York | New York | 10019 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Rochester Skin Lymphoma Medical Group | Rochester | New York | 14450 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| The Ohio State University and Wexner Medical Center, James Cancer Hospital | Columbus | Ohio | 43210 | — |
| University of Oklahoma Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| West Penn Hospital | Pittsburgh | Pennsylvania | 15224 | — |
| Hollings Cancer Center | Charleston | South Carolina | 29425 | — |
| Vanderbilt Ingram Cancer Center | Nashville | Tennessee | 37212 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| CliniCore Texas | Houston | Texas | 77079 | — |
| START- South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| Virgina Commonwealth University | Richmond | Virginia | 23298 | — |
| University of Washington, Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02503423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02503423 live on ClinicalTrials.gov.